You have 9 free searches left this month | for more free features.

Gemtuzumab Ozogamicin Gilteritinib Combination

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Acute Myeloid Leukemia Trial in Memphis (Venetoclax, Azacitidine, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jul 21, 2023

Acute Myeloid Leukemia Trial in Baltimore (Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Dose Escalation -tagraxofusp-erzs
  • Dose Expansion at RP2D -tagraxofusp-erzs
  • Baltimore, Maryland
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jan 27, 2023

Acute Myeloid Leukemia Trial in Tampa (Vyxeos, Gemtuzumab Ozogamicin)

Recruiting
  • Acute Myeloid Leukemia
  • Tampa, Florida
    Moffitt Cancer Center
Sep 23, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +5 more
  • Gemtuzumab Ozogamicin
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Acute Myeloid Leukemia Trial in Seattle (drug, biological, other)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 10, 2022

Acute Myeloid Leukemia Trial in Pittsburgh (mitoxantrone + etoposide + gemtuzumab ozogamicin)

Recruiting
  • Acute Myeloid Leukemia
  • mitoxantrone + etoposide + gemtuzumab ozogamicin
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Feb 9, 2022

Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

Active, not recruiting
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • Gemtuzumab Ozogamicin
  • Valhalla, New York
    New York Medical College
Nov 11, 2021

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +3 more
  • Gemtuzumab Ozogamicin
  • Liposome-encapsulated Daunorubicin-Cytarabine
  • Houston, Texas
    M D Anderson Cancer Center
Jun 2, 2021

Acute Myeloid Leukemia Trial in New York (CPX-351, Gemtuzumab Ozogamicin)

Recruiting
  • Acute Myeloid Leukemia
  • New York, New York
    Weill Cornell Medical College
Dec 21, 2021

Acute Myeloid Leukemia Trial in Germany (MODULE: conventional chemo (Cytarabine+Daunorubicin) in combination with

Active, not recruiting
  • Acute Myeloid Leukemia
  • MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO
  • +4 more
  • München, Bayern, Germany
  • +10 more
Aug 31, 2021

Acute Myeloid Leukemia Trial in Canada, Puerto Rico, United States (procedure, drug, behavioral)

Recruiting
  • Acute Myeloid Leukemia
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +13 more
  • Birmingham, Alabama
  • +187 more
Apr 28, 2022

Acute Myeloid Leukemia Trial in Austria, Germany (Gemtuzumab Ozogamicin (Mylotarg), standard chemo)

Completed
  • Acute Myeloid Leukemia
  • Gemtuzumab Ozogamicin (Mylotarg)
  • standard chemotherapy
  • Graz, Austria
  • +59 more
Sep 28, 2021

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Baltimore, Buffalo (Gemtuzumab Ozogamicin,

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Gemtuzumab Ozogamicin
  • +4 more
  • Baltimore, Maryland
  • +1 more
Dec 13, 2022

Acute Myeloid Leukemia Trial in Germany (Venetoclax plus Azacitidine, standard of care chemo plus gemtuzumab ozogamicin)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Venetoclax plus Azacitidine
  • standard of care chemotherapy plus gemtuzumab ozogamicin
  • Essen, NRW, Germany
  • +17 more
Jun 6, 2023

Acute Myeloid Leukaemia Trial in Worldwide (Gemtuzumab ozogamicin, Liposomal daunorubicin, Mitoxantrone)

Recruiting
  • Acute Myeloid Leukaemia
  • Gemtuzumab ozogamicin
  • +6 more
  • Adelaide, Australia
  • +67 more
Sep 30, 2021

Novo Acute Myeloid Leukemia Trial in Spain (Mylotarg)

Completed
  • Novo Acute Myeloid Leukemia
  • Badalona, Barcelona, Spain
  • +5 more
Jan 26, 2021

Leukemia, Myeloid, Acute Trial in Jerusalem (Vyxeos, Mylotarg)

Recruiting
  • Leukemia, Myeloid, Acute
  • Jerusalem, Yerushalayim, Israel
    Shaare Zedek Medical Center
Oct 25, 2022

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody

Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Anti-OX40 Agonist Monoclonal Antibody PF-04518600
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 25, 2022

Leukemia Trial in United States (arsenic trioxide, gemtuzumab ozogamicin, mercaptopurine)

Completed
  • Leukemia
  • arsenic trioxide
  • +4 more
  • Roseville, California
  • +191 more
Dec 14, 2022

Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

Active, not recruiting
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • Gemtuzumab Ozogamicin
  • Valhalla, New York
    New York Medical College
Sep 26, 2022

Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia Trial in United States

Active, not recruiting
  • Acute Myeloid Leukemia
  • +13 more
  • Burbank, California
  • +176 more
Mar 25, 2022

Acute Myeloid Leukemia (AML) Trial in France

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
    • Amiens, France
    • +28 more
    Jul 21, 2021

    Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)

    Not yet recruiting
    • Acute Myeloid Leukemia (AML)
    • Basking Ridge, New Jersey
    • +6 more
    Mar 3, 2023

    Leukemia Trial in United States (mercaptopurine, methotrexate, tretinoin)

    Completed
    • Leukemia
    • Scottsdale, Arizona
    • +209 more
    Dec 14, 2022

    AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

    Not yet recruiting
    • AML
    • +11 more
    • (no location specified)
    Aug 14, 2023